News

Abstral is a rapid dissolving, sub-lingual tablet of fentanyl, indicated for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. Abstral is currently

This tranche was dominated by a new investment from Baxter International to go along with the September 2008 investments by new investors Genzyme Ventures and Mitsubishi UFJ Capital.

The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC osteoarthritis (OA) score from baseline to day 21

Aplenzin, which was approved by the FDA in April 2008, is indicated for the treatment of major depressive disorder. Biovail anticipates that Sanofi Aventis US will launch the

In Phase III studies Firmagon (degarelix) produced a significant reduction in levels of testosterone within three days in more than 96% of study patients. Testosterone plays a major

From 2005 to 2008, Mr Bowen was vice president and CFO for GSI Group. At GSI Group, Mr Bowen led the consolidation of the company’s financial operations, implemented

Terms of the transaction provide for St Jude Medical to pay $138 million of the purchase price in December 2008, with the balance due in two subsequent payments

Replace is a double-blind, placebo-controlled trial that will randomize approximately 110 patients at over a dozen sites in the US, Canada and Europe. The primary objective is to

For this expansion, Galapagos receives a payment of E2 million cash from GlaxoSmithKline (GSK). This payment is in addition to the existing alliance terms, making the total alliance